NICE

This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering the entire life-cycle, the value added by SGAs to the system is higher than the expected value estimated at launch. P&R decisions should consider the value added by medicines over the long-run.

Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. A new OHE report provides empirical evidence on the relationship between health outcomes and health expenditures in England. Results suggest that setting a cost-effectiveness criterion for NICE may not be capable of being synthesised using scientific methods alone, but involve political judgements.

OHE’s Koonal Shah gave a presentation on societal values and the provision of end of life treatments at a Manchester Centre for Health Economics seminar.

OHE has submitted a response to the public consultation on updating the principles that guide the development of NICE guidance and standards.

OHE’s Koonal Shah and Oliver Rivero-Arias presented at a NICE Technical Forum on the topic of valuing health in children and adolescents.

When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.

This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.

We conducted a literature review in order to identify whether long-term cancer survivors’ quality of life is comparable to that of the general population.

Just published in Social Science & Medicine: a review of stated preferences examining the extent of support for an end of life premium.

Pages

Subscribe to RSS - NICE